Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
175%(7 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_1
3
43%
Ph phase_2
3
43%
Ph phase_3
1
14%

Phase Distribution

3

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
57.1%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 23 (42.9%)
Phase 31 (14.3%)

Trials by Status

completed457%
terminated343%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_3

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

NCT03890120
terminatedphase_1

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

NCT04060147
completedphase_2

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT03987074
completedphase_2

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

NCT02943460
completedphase_1

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

NCT02808312
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03890120Phase 3

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

Terminated
NCT04060147Phase 1

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Terminated
NCT03987074Phase 2

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

Completed
NCT02943460Phase 2

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Completed
NCT02808312Phase 1

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Completed
NCT02654002Phase 1

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

Completed
NCT02943447Phase 2

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7